Лучшие больницы для «Thyroid Cancer Treatment» в Ченнаи, Индия

Thyroid cancer arises from the follicular epithelial cells or parafollicular C-cells of the thyroid gland and is classified into four principal histological subtypes: papillary thyroid carcinoma (PTC, ~85% of cases), follicular thyroid carcinoma (FTC, ~10%), medullary thyroid carcinoma (MTC, ~3%), and anaplastic thyroid carcinoma (ATC, <2%). PTC and FTC are collectively termed differentiated thyroid cancers (DTC) and carry the most favourable prognosis because they retain iodine-uptake capability, making them amenable to RAI ablation. MTC originates from calcitonin-secreting parafollicular cells and is associated with RET proto-oncogene mutations, both germline (in the context of MEN2A and MEN2B syndromes) and somatic. ATC is the rarest but most aggressive subtype, frequently presenting with rapid cervical mass expansion, tracheal compression, dysphagia, and hoarseness, demanding an urgent multimodal response.

• Confirmed thyroid nodule(s) with fine-needle aspiration cytology (FNAC) reported as Bethesda Category V (suspicious for malignancy) or VI (malignant)
• Histopathologically proven PTC, FTC, Hurthle cell carcinoma, MTC, or ATC on core needle biopsy or post-lobectomy pathology
• Patients with compressive symptoms: progressive dysphagia, stridor, voice hoarseness, or superior vena cava syndrome from a large thyroid mass
• MEN2 syndrome carriers or RET mutation-positive individuals (germline testing recommended before prophylactic thyroidectomy)
• Recurrent or metastatic DTC progressing on or ineligible for RAI therapy, requiring multikinase inhibitor initiation
• +1 more

Required Diagnostics (pre-treatment work-up):

• High-resolution neck ultrasound with nodule mapping (ACR TIRADS or ATA classification)
• Fine-needle aspiration cytology (FNAC) with or without BRAF/RAS/RET molecular testing (ThyroSeq v3 or Afirma GSC for indeterminate nodules)
• Serum TSH, Free T3, Free T4, Anti-TPO, Anti-Tg antibodies
• Serum calcitonin and CEA (mandatory if MTC suspected)
• Serum calcium, PTH, and Vitamin D (parathyroid baseline)
• +5 more

Thyroid cancer treatment is subtype-specific and stage-dependent. The following modalities are deployed individually or in multimodal combination:

1. SURGICAL APPROACHES

Total Thyroidectomy (TT): The cornerstone of treatment for tumours >1 cm, bilateral disease, extrathyroidal extension, or any MTC/ATC. Performed under general anaesthesia via a low cervical collar incision (Kocher incision). Intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve (RLN) is standard at high-volume centres. Parathyroid identification and autotransplantation are performed to minimise post-operative hypoparathyroidism.

Hemithyroidectomy / Thyroid Lobectomy: Appropriate for confirmed low-risk PTC ≤4 cm confined to one lobe without nodal involvement, per ATA 2015 guidelines. Reduces lifelong levothyroxine dependency risk while maintaining curative intent.

PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel)

• GAF Healthcare case manager reviews uploaded medical records, biopsy reports, ultrasound images, and prior treatment history.
• Multidisciplinary tumour board (endocrine surgeon, nuclear medicine physician, medical oncologist, endocrinologist) at the partner hospital reviews the case and formulates a personalised treatment plan.
• Patient receives a detailed cost estimate, treatment protocol summary, and hospital admission confirmation.
• E-Medical Visa application (India) or entry visa assistance (UAE) initiated by GAF Healthcare.
• Pre-operative laboratory work (CBC, metabolic panel, coagulation, thyroid function, calcitonin, PTH) and any outstanding imaging (PET-CT, CT contrast) arranged on Day 1–2 of arrival.

PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Day 1–3)